VERICEL CORPORATION Revenue Breakdown
No Revenue Breakdown for VCEL on this site yet.
- 2025-12-31: Others Not split by product in the filing$276.26M100.00%; Total revenue $276.26M.
- 2024-12-31: Others Not split by product in the filing$237.22M100.00%; Total revenue $237.22M.
- 2023-12-31: Others Not split by product in the filing$197.52M100.00%; Total revenue $197.52M.
- 2022-12-31: Others Not split by product in the filing$163.70M100.00%; Total revenue $163.70M.
Source checked: the stored Revenue Breakdown page for VCEL.
Revenue by product
Each year (12 month)
| Fiscal year end | Others | Total revenue |
|---|---|---|
| 2025-12-31 | Not split by product in the filing $276.26M 100.00% | $276.26M |
| 2024-12-31 | Not split by product in the filing $237.22M 100.00% | $237.22M |
| 2023-12-31 | Not split by product in the filing $197.52M 100.00% | $197.52M |
| 2022-12-31 | Not split by product in the filing $163.70M 100.00% | $163.70M |
| 2021-12-31 | Not split by product in the filing $153.07M 100.00% | $153.07M |
| 2020-12-31 | Not split by product in the filing $121.97M 100.00% | $121.97M |
| 2019-12-31 | Not split by product in the filing $117.85M 100.00% | $117.85M |
| 2018-12-31 | Not split by product in the filing $90.86M 100.00% | $90.86M |
| 2017-12-31 | Not split by product in the filing $62.76M 100.00% | $62.76M |
| 2016-12-31 | Not split by product in the filing $54.38M 100.00% | $54.38M |
| 2015-12-31 | Not split by product in the filing $51.17M 100.00% | $51.17M |
| 2014-12-31 | Not split by product in the filing $28.80M 100.00% | $28.80M |
| 2013-12-31 | $19.00K | |
| 2012-12-31 | $21.00K | |
| 2011-12-31 | $18.00K | |
| 2010-06-30 | $89.00K | |
| 2009-06-30 | $182.00K |
Each quarter (3 month)
| Quarter end | Others | Total revenue |
|---|---|---|
| 2026-06-30 | Not split by product $77.46M 100.00% | $77.46M |
| 2026-03-31 | Not split by product $68.42M 100.00% | $68.42M |
| 2025-12-31 | Not split by product $92.92M 100.00% | $92.92M |
| 2025-09-30 | Not split by product $67.50M 100.00% | $67.50M |
| 2025-06-30 | Not split by product $63.24M 100.00% | $63.24M |
| 2025-03-31 | Not split by product $52.60M 100.00% | $52.60M |
| 2024-12-31 | Not split by product $75.38M 100.00% | $75.38M |
| 2024-09-30 | Not split by product $57.91M 100.00% | $57.91M |
| 2024-06-30 | Not split by product $52.66M 100.00% | $52.66M |
| 2024-03-31 | Not split by product $51.28M 100.00% | $51.28M |
| 2023-12-31 | Not split by product $65.00M 100.00% | $65.00M |
| 2023-09-30 | Not split by product $45.58M 100.00% | $45.58M |
| 2023-06-30 | Not split by product $45.92M 100.00% | $45.92M |
| 2023-03-31 | Not split by product $41.02M 100.00% | $41.02M |
| 2022-12-31 | Not split by product $52.69M 100.00% | $52.69M |
| 2022-09-30 | Not split by product $38.33M 100.00% | $38.33M |
| 2022-06-30 | Not split by product $36.83M 100.00% | $36.83M |
| 2022-03-31 | Not split by product $35.85M 100.00% | $35.85M |
| 2021-12-31 | Not split by product $47.05M 100.00% | $47.05M |
| 2021-09-30 | Not split by product $33.72M 100.00% | $33.72M |
| 2021-06-30 | Not split by product $38.68M 100.00% | $38.68M |
| 2021-03-31 | Not split by product $33.63M 100.00% | $33.63M |
| 2020-12-31 | Not split by product $44.26M 100.00% | $44.26M |
| 2020-09-30 | Not split by product $31.02M 100.00% | $31.02M |
| 2020-06-30 | Not split by product $20.01M 100.00% | $20.01M |
| 2020-03-31 | Not split by product $26.68M 100.00% | $26.68M |
| 2019-12-31 | Not split by product $39.39M 100.00% | $39.39M |
| 2019-09-30 | Not split by product $30.50M 100.00% | $30.50M |
| 2019-06-30 | Not split by product $26.15M 100.00% | $26.15M |
| 2019-03-31 | Not split by product $21.81M 100.00% | $21.81M |
| 2018-12-31 | Not split by product $31.34M 100.00% | $31.34M |
| 2018-09-30 | Not split by product $22.48M 100.00% | $22.48M |
| 2018-06-30 | Not split by product $19.01M 100.00% | $19.01M |
| 2018-03-31 | Not split by product $18.03M 100.00% | $18.03M |
| 2017-12-31 | Not split by product $22.19M 100.00% | $22.19M |
| 2017-09-30 | Not split by product $14.26M 100.00% | $14.26M |
| 2017-06-30 | Not split by product $16.95M 100.00% | $16.95M |
| 2017-03-31 | Not split by product $9.36M 100.00% | $9.36M |
| 2016-12-31 | Not split by product $23.35M 100.00% | $23.35M |
| 2016-09-30 | Not split by product $10.93M 100.00% | $10.93M |
| 2016-06-30 | Not split by product $12.82M 100.00% | $12.82M |
| 2016-03-31 | Not split by product $14.11M 100.00% | $14.11M |
| 2015-12-31 | Not split by product $15.42M 100.00% | $15.42M |
| 2015-09-30 | Not split by product $11.31M 100.00% | $11.31M |
| 2015-06-30 | Not split by product $13.59M 100.00% | $13.59M |
| 2015-03-31 | Not split by product $10.85M 100.00% | $10.85M |
| 2014-12-31 | Not split by product $14.71M 100.00% | $14.71M |
| 2014-09-30 | Not split by product $9.66M 100.00% | $9.66M |
| 2014-06-30 | Not split by product $4.43M 100.00% | $4.43M |
| 2014-03-31 | Not split by product $0.00 | $0.00 |
| 2013-12-31 | Not split by product $8.00K 100.00% | $8.00K |
| 2013-09-30 | Not split by product $0.00 | $0.00 |
| 2013-06-30 | Not split by product $3.00K 100.00% | $3.00K |
| 2013-03-31 | Not split by product $8.00K 100.00% | $8.00K |
| 2012-12-31 | Not split by product $19.00K 100.00% | $19.00K |
| 2012-09-30 | Not split by product $0.00 | $0.00 |
| 2012-06-30 | Not split by product $0.00 | $0.00 |
| 2012-03-31 | Not split by product $2.00K 100.00% | $2.00K |
| 2011-12-31 | Not split by product $0.00 | $0.00 |
| 2011-09-30 | Not split by product $9.00K 100.00% | $9.00K |
| 2011-06-30 | Not split by product $0.00 | $0.00 |
| 2011-03-31 | Not split by product $9.00K 100.00% | $9.00K |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |